Nomigrin (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium reduces inflammation by inhibiting cyclooxygenase enzymes, lowering prostaglandin production. Sumatriptan succinate activates 5‑HT1B/1D receptors, causing cranial blood‑vessel constriction and blocking neuropeptide release, together aborting migraine pain pathways.

The dose of Nomigrin is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nomigrin in pregnancy or while breastfeeding has not been fully established. Healthcare providers should weigh potential benefits against risks and consider alternative therapies if there are concerns about fetal or infant exposure.

To order Nomigrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nomigrin combines an NSAID with a triptan, offering both anti‑inflammatory pain relief and targeted vasoconstriction. This dual mechanism can be more effective for some patients than using a single‑agent triptan or NSAID alone, but individual response varies and should be evaluated by a clinician.

Nomigrin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Nomigrin is taken orally with a full glass of water, preferably at the first sign of a migraine attack. It should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include coronary artery spasm, myocardial ischemia, serotonin syndrome when combined with other serotonergic drugs, severe allergic reactions, gastrointestinal bleeding, and rare events such as stroke. Patients should seek immediate medical attention if they experience chest pain, severe allergic signs, or neurological changes.

Nomigrin should be avoided in patients with known hypersensitivity to naproxen, sumatriptan, or any component of the formulation, those with uncontrolled hypertension, recent myocardial infarction, severe coronary artery disease, or who are currently taking MAO inhibitors, other triptans, or strong serotonergic agents.